“…Remarkably, induction of heparanase prior to the appearance of malignancy was reported in essentially all of the above-mentioned inflammatory conditions, i.e., Barrett's oesophagus (Brun et al, 2009; Sonoda et al, 2010), hepatitis C infection (El-Assal et al, 2001), chronic pancreatitis (Koliopanos et al, 2001), Crohn disease and ulcerative colitis (Lerner et al, 2011; Waterman et al, 2007). Given the causal role the enzyme plays in tumor progression in tissues in which cancer-related inflammation typically occurs [i.e., gastrointestinal tract, pancreas, liver (Brun et al, 2009; El-Assal et al, 2001; Hoffmann et al, 2008; Koliopanos et al, 2001; Naomoto et al, 2005; Nobuhisa et al, 2005; Sonoda et al, 2010; Xiong et al, 2012; Zhang et al, 2007)], it is conceivable that inflammation-induced heparanase may be involved in coupling inflammation and cancer. The findings obtained in a study utilizing mouse model of colitis-associated colon carcinoma support this notion (Lerner et al, 2011).…”